{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:33:04Z","timestamp":1793644384804,"version":"4.5.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.xphs.2022.08.022","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T22:58:06Z","timestamp":1661295486000},"page":"3318-3326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["A new Febuxostat-Telmisartan Drug-Drug Cocrystal for Gout-Hypertension Combination Therapy"],"prefix":"10.1016","volume":"111","author":[{"given":"Thipashini","family":"Ganesan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2136-3903","authenticated-orcid":false,"given":"Prakash","family":"Muthudoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7768-4813","authenticated-orcid":false,"given":"Raja Sekhar","family":"Voguri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9107-6080","authenticated-orcid":false,"given":"Subhas","family":"Ghosal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddy Yii Chung","family":"Ann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayson","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajid Syed","family":"Shahnawaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9589-0143","authenticated-orcid":false,"given":"Muhammad Firdaus","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0932-471X","authenticated-orcid":false,"given":"Ravikiran","family":"Allada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7849-6929","authenticated-orcid":false,"given":"Hong Heng","family":"See","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2022.08.022_bib0001","doi-asserted-by":"crossref","unstructured":"Brittain HG.Polymorphism in Pharmaceutical Solids. (Brittain HG, ed.). CRC Press; 2018. doi:10.3109\/9781420073225","DOI":"10.3109\/9781420073225"},{"issue":"4","key":"10.1016\/j.xphs.2022.08.022_bib0002","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1023\/A:1023285627778","article-title":"Scientific considerations of pharmaceutical solid polymorphism in abbreviated new drug applications","volume":"20","author":"Yu","year":"2003","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.xphs.2022.08.022_bib0003","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ceat.200500397","article-title":"Polymorphism of active pharmaceutical ingredients","volume":"29","author":"Karpinski","year":"2006","journal-title":"Chem Eng Technol"},{"issue":"3","key":"10.1016\/j.xphs.2022.08.022_bib0004","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3390\/pharmaceutics10030074","article-title":"Pharmaceutical dispersion techniques for dissolution and bioavailability enhancement of poorly water-soluble drugs","volume":"10","author":"Zhang","year":"2018","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.xphs.2022.08.022_bib0005","doi-asserted-by":"crossref","first-page":"5604","DOI":"10.3390\/app11125604","article-title":"Study of different crystal habits of aprepitant: dissolution and material attributes","volume":"11","author":"Datir","year":"2021","journal-title":"Appl Sci"},{"issue":"3","key":"10.1016\/j.xphs.2022.08.022_bib0006","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.addr.2003.10.005","article-title":"General principles of pharmaceutical solid polymorphism A supramolecular perspective","volume":"56","author":"Rodr\u00edguez-Spong","year":"2004","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.xphs.2022.08.022_bib0007","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0169-409X(01)00098-9","article-title":"Amorphous pharmaceutical solids: preparation, characterization and stabilization","volume":"48","author":"Yu","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2022.08.022_bib0008","series-title":"Guidance for Industry Q8(R2) Pharmaceutical Development","year":"2009"},{"key":"10.1016\/j.xphs.2022.08.022_bib0009","series-title":"The Handbook of Medicinal Chemistry","first-page":"566","article-title":"CHAPTER 22. Pharmaceutical Properties\u2014the Importance of Solid Form Selection","author":"Docherty","year":"2015"},{"key":"10.1016\/j.xphs.2022.08.022_bib0010","series-title":"The 2nd International Online Conference on Crystals","first-page":"14","article-title":"Pharmaceutical cocrystals\u2014a review","author":"Buddhadev","year":"2021"},{"issue":"27","key":"10.1016\/j.xphs.2022.08.022_bib0011","doi-asserted-by":"crossref","first-page":"9952","DOI":"10.1021\/ja403264c","article-title":"Crystal engineering: from molecule to crystal","volume":"135","author":"Desiraju","year":"2013","journal-title":"J Am Chem Soc"},{"issue":"54","key":"10.1016\/j.xphs.2022.08.022_bib0012","doi-asserted-by":"crossref","first-page":"8342","DOI":"10.1039\/C6CC02943D","article-title":"Pharmaceutical cocrystals: walking the talk","volume":"52","author":"Bolla","year":"2016","journal-title":"Chem Commun"},{"key":"10.1016\/j.xphs.2022.08.022_bib0013","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/2667387815666210203151209","article-title":"Co-crystals for generic pharmaceuticals: an outlook on solid oral dosage formulations","author":"Rajendran","year":"2021","journal-title":"Recent Adv Drug Deliv Formul"},{"issue":"6","key":"10.1016\/j.xphs.2022.08.022_bib0014","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1021\/acs.cgd.1c00229","article-title":"Drug\u2013drug cocrystallization simultaneously improves pharmaceutical properties of genistein and ligustrazine","volume":"21","author":"Li","year":"2021","journal-title":"Cryst Growth Des"},{"issue":"4","key":"10.1016\/j.xphs.2022.08.022_bib0015","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1021\/acs.cgd.6b01848","article-title":"Co-crystal of tramadol hydrochloride\u2013celecoxib (ctc): a novel API\u2013API co-crystal for the treatment of pain","volume":"17","author":"Almansa","year":"2017","journal-title":"Cryst Growth Des"},{"issue":"5","key":"10.1016\/j.xphs.2022.08.022_bib0016","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1021\/acs.cgd.9b01688","article-title":"Drug\u2013drug cocrystals provide significant improvements of drug properties in treatment with progesterone","volume":"20","author":"Guo","year":"2020","journal-title":"Cryst Growth Des"},{"issue":"3","key":"10.1016\/j.xphs.2022.08.022_bib0017","first-page":"307","article-title":"Drug-drug cocrystals: opportunities and challenges","volume":"16","author":"Wang","year":"2021","journal-title":"Asian J Pharm Sci"},{"issue":"37","key":"10.1016\/j.xphs.2022.08.022_bib0018","doi-asserted-by":"crossref","first-page":"6137","DOI":"10.1039\/D0CE00353K","article-title":"Drug\u2013drug cocrystals of anticancer drugs erlotinib\u2013furosemide and gefitinib\u2013mefenamic acid for alternative multi-drug treatment","volume":"22","author":"George C","year":"2020","journal-title":"CrystEngComm"},{"issue":"6","key":"10.1016\/j.xphs.2022.08.022_bib0019","first-page":"330","article-title":"(Sacubitril\/Valsartan): first-in-class angiotensin receptor neprilysin inhibitor FDA approved for patients with heart failure","volume":"8","author":"Entresto","year":"2015","journal-title":"Am Heal drug benefits"},{"issue":"3","key":"10.1016\/j.xphs.2022.08.022_bib0021","doi-asserted-by":"crossref","first-page":"355","DOI":"10.15171\/apb.2018.042","article-title":"A review about regulatory status and recent patents of pharmaceutical co-crystals","volume":"8","author":"Kumar","year":"2018","journal-title":"Adv Pharm Bull"},{"issue":"10","key":"10.1016\/j.xphs.2022.08.022_bib0023","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1248\/cpb.c16-00233","article-title":"Characterization and quality control of pharmaceutical cocrystals","volume":"64","author":"Izutsu","year":"2016","journal-title":"Chem Pharm Bull)"},{"key":"10.1016\/j.xphs.2022.08.022_bib0024","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.addr.2017.09.014","article-title":"Pharmaceutical cocrystals, salts and polymorphs: advanced characterization techniques","volume":"117","author":"Pindelska","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"issue":"8","key":"10.1016\/j.xphs.2022.08.022_bib0025","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41440-020-0481-6","article-title":"Uric acid and hypertension","volume":"43","author":"Lanaspa","year":"2020","journal-title":"Hypertens Res"},{"key":"10.1016\/j.xphs.2022.08.022_bib0026","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.addr.2017.07.001","article-title":"Pharmaceutical aspects of salt and cocrystal forms of APIs and characterization challenges","volume":"117","author":"Cerreia Vioglio","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2022.08.022_bib0027","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/9781118903681.ch12","article-title":"Biorelevant dissolution testing","author":"Almukainzi","year":"2014","journal-title":"Therapeutic Delivery Solutions"},{"issue":"2","key":"10.1016\/j.xphs.2022.08.022_bib0028","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1107\/S0021889808042726","article-title":"OLEX2\u00a0: a complete structure solution, refinement and analysis program","volume":"42","author":"Dolomanov","year":"2009","journal-title":"J Appl Crystallogr"},{"issue":"1","key":"10.1016\/j.xphs.2022.08.022_bib0029","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1107\/S2053273314026370","article-title":"SHELXT \u2013 integrated space-group and crystal-structure determination","volume":"71","author":"Sheldrick","year":"2015","journal-title":"Acta Crystallogr Sect A Found Adv"},{"issue":"1","key":"10.1016\/j.xphs.2022.08.022_bib0030","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1107\/S1600576719014092","article-title":"Mercury 4.0\u00a0: from visualization to analysis, design and prediction","volume":"53","author":"Macrae","year":"2020","journal-title":"J Appl Crystallogr"},{"issue":"10","key":"10.1016\/j.xphs.2022.08.022_bib0031","doi-asserted-by":"crossref","first-page":"507","DOI":"10.4319\/lom.2010.8.507","article-title":"Using laser diffraction data to obtain accurate particle size distributions: the role of particle composition","volume":"8","author":"Andrews","year":"2010","journal-title":"Limnol Oceanogr Methods"},{"issue":"1-4","key":"10.1016\/j.xphs.2022.08.022_bib0032","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ppsc.19870040104","article-title":"Laser Diffraction Spectrometry: Fraunhofer Diffraction Versus Mie Scattering","volume":"4","author":"de Boer","year":"1987","journal-title":"Part Part Syst Charact"},{"key":"10.1016\/j.xphs.2022.08.022_bib0033","series-title":"Regulatory Classification of Pharmaceutical Co-Crystals Guidance for Industry","year":"2018"},{"issue":"19","key":"10.1016\/j.xphs.2022.08.022_bib0034","first-page":"1","article-title":"Polymorphs of Febuxostat","volume":"1","year":"2012","journal-title":"EP Pat 0879946A2"},{"key":"10.1016\/j.xphs.2022.08.022_bib0035","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jpba.2015.01.005","article-title":"Quantification of febuxostat polymorphs using powder X-ray diffraction technique","volume":"107","author":"Qiu","year":"2015","journal-title":"J Pharm Biomed Anal"},{"issue":"11","key":"10.1016\/j.xphs.2022.08.022_bib0036","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/1520-6017(200011)89:11<1465::AID-JPS9>3.0.CO;2-C","article-title":"Structural characterization of three crystalline modifications of telmisartan by single crystal and high-resolution x-ray powder diffraction","volume":"89","author":"Dinnebier","year":"2000","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2022.08.022_bib0037","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1021\/cg9001994","article-title":"Salt or cocrystal? A new series of crystal structures formed from simple pyridines and carboxylic acids","volume":"9","author":"Mohamed","year":"2009","journal-title":"Cryst Growth Des"},{"issue":"3","key":"10.1016\/j.xphs.2022.08.022_bib0038","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1021\/mp0601345","article-title":"The salt\u2212cocrystal continuum: the influence of crystal structure on ionization state","volume":"4","author":"Childs","year":"2007","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2022.08.022_bib41","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1039\/c2ce26055g","article-title":"Acid\u2013base crystalline complexes and the pKa rule","volume":"14","author":"Cruz-Cabeza","year":"2012","journal-title":"CrystEngComm"},{"key":"10.1016\/j.xphs.2022.08.022_bib0039","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.carbpol.2015.06.098","article-title":"The effect of mechanical grinding on the formation, crystalline changes and dissolution behaviour of the inclusion complex of telmisartan and \u03b2-cyclodextrins","volume":"133","author":"Borba","year":"2015","journal-title":"Carbohydr Polym"},{"issue":"2","key":"10.1016\/j.xphs.2022.08.022_bib0040","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1208\/s12249-017-0905-z","article-title":"Improving solubility and oral bioavailability of febuxostat by polymer-coated nanomatrix","volume":"19","author":"Yin","year":"2018","journal-title":"AAPS PharmSciTech"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354922003574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354922003574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:40:38Z","timestamp":1758361238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354922003574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0022354922003574"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2022.08.022","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new Febuxostat-Telmisartan Drug-Drug Cocrystal for Gout-Hypertension Combination Therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2022.08.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}